Structure-Based Virtual Screening to Identify Negative Allosteric Modulators of NMDA.

Area of Science:

• Neuroscience
• Pharmacology
• Computational Chemistry

Background:

• N-methyl-D-aspartate (NMDA) receptors, crucial for brain functions like learning and memory, are implicated in neurodegenerative diseases when overstimulated.
• Overactivation of NMDA receptors contributes to excitotoxicity, a mechanism involved in acute injuries (stroke, TBI) and chronic conditions (Alzheimer's, Parkinson's).

Purpose of the Study:

• To design novel, blood-brain barrier-permeable therapeutic compounds targeting an allosteric site on GluN2A-containing NMDA receptors.
• To identify potential drug candidates for treating acute and chronic neurological disorders associated with NMDA receptor dysfunction.

Main Methods:

• Utilized pharmacophore-based virtual screening, molecular docking, and computational ADME predictions.
• Employed molecular dynamics (MD) simulations to assess compound stability and binding interactions.
• Screened the ChEMBL database for potential NMDA receptor inhibitors.

Main Results:

• Identified five compounds from the ChEMBL database predicted to be potential NMDA receptor inhibitors.
• Validated these compounds through pharmacophore screening, score-based assessments, and MD simulations.
• Confirmed that the identified compounds allosterically inhibit NMDA receptors and possess favorable pharmacokinetic profiles.

Conclusions:

• The study successfully identified five novel compounds with the potential to allosterically inhibit NMDA receptors.
• These compounds demonstrate favorable pharmacokinetic properties, suggesting their suitability for further in vitro and in vivo testing.
• The identified molecules represent promising therapeutic agents for neurological conditions linked to NMDA receptor excitotoxicity.